In a nutshell
This study compared the effectiveness of the International Prognostic Scoring System (IPSS) measuring 7 factors (IPSS7) versus the IPSS measuring 3 factors (IPSS3) in predicting outcomes for patients with Hodgkin's lymphoma (HL). This study concluded that there was no significant difference between these scoring systems.
The International Prognostic Scoring System (IPSS) is commonly used to predict outcomes for patients with advanced HL. The IPSS7 measures 7 disease-related factors. These include the patient's age and sex, disease stage, and the levels of certain cell types in the blood. The IPSS3 measures 3 factors. These include the patient's age, disease stage, and hemoglobin levels in the blood.
Recent studies have suggested that the IPSS7 may not be as effective as the IPSS3, as it is often difficult to measure all 7 factors. Whether the IPSS3 is better at predicting outcomes for patients with HL remains unclear.
Methods & findings
This study included the medical records of 314 patients with advanced HL. The ability of several different HL-associated factors to predict the outcomes of HL was measured. The IPSS7 scoring system was analyzed in 73% of patients. The IPSS3 scoring system was analyzed in all patients. Most patients were treated with chemotherapy. Patients were followed-up for an average of 57 months.
Overall, 85% of patients responded to treatment. 81% of patients had a complete disappearance of all signs of cancer. At follow-up, 13% of patients had the cancer come back (relapse).
At 5 years, 72% of patients did not experience relapse or have tumor growth or spread. 82% of patients were still alive 5 years later.
There were no differences in the effectiveness of the IPSS3 versus the IPSS7 systems in predicting overall survival. However, the IPSS3 scoring system was significantly associated with a 2.7-fold odds of predicting survival without tumor growth or spread.
The bottom line
This study concluded that the IPSS3 and IPSS7 scoring systems were similar in their ability to predict the outcomes of HL.
The fine print
This study analyzed the medical records of patients. This study was retrospective, meaning it looked back in time to analyze data. This may limit the conclusions that can be drawn from these results.
Published By :
Clinical lymphoma, myeloma & leukemia
Feb 01, 2019
If you sign up for Medivizor, you'll receive PERSONALIZED updates that are JUST FOR YOU. Want to give it a try?